<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525952</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2015-01-012</org_study_id>
    <nct_id>NCT02525952</nct_id>
  </id_info>
  <brief_title>Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System</brief_title>
  <official_title>A Randomized Controlled Trial to Compare the Outcomes Between Hepatectomy and Transarterial Chemoembolization for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish a selection criteria of hepatectomy for patients with&#xD;
      multiple hepatocellular carcinomas based on the NDR Scoring System&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple hepatocellular carcinomas (HCCs) accounts for 60% to 70% of patients with&#xD;
      hepatocellular carcinoma.However,the selection criteria of hepatectomy for patients with&#xD;
      multiple HCCs remains controversial.Researches have suggested that part of the patients with&#xD;
      multiple HCCs can also benefit from hepatectomy.But,expanding the selection criteria for&#xD;
      hepatectomy will increase tumor recurrence rates and reduce the therapeutic effect, more&#xD;
      stringent selection criteria will also make part of the patients who should take hepatectomy&#xD;
      lose the operation chance. This is a difficult problem in the research of this field.The&#xD;
      Barcelona Clinic Liver Cancer (BCLC) system recommends that stage A (number ≤ 3, largest&#xD;
      diameter ≤ 3 cm) were suitable for liver resection.However, increasing reports on good&#xD;
      outcome after hepatectomy for patients with multiple HCCs have been published.Studies on&#xD;
      clonal origin suggest that hepatectomy is a better treatment for multiple HCCs from&#xD;
      multicentric origin (MO) than that from intrahepatic metastasis (IM) and the 5-year overall&#xD;
      survival rates is 24% to 58%.The investigators established a scoring system(NDR score; N,&#xD;
      tumor number; D, total tumor diameter; R, ratio of largest/smallest diameter) based on&#xD;
      preoperative data which can accurately predict postoperative long-term survival of patients&#xD;
      with multiple HCCs.The formula is as follows: 1×N（N: &gt;3=1; ≤3= 0）+ 2×D（D: &gt;8cm = 1; ≤8cm= 0）+&#xD;
      1×R（R: &gt;6 = 1; ≤6= 0）.The investigators first propose a selection criteria of hepatectomy for&#xD;
      patients with multiple HCCs based on this scoring system. Patients with a NDR score 0-2 are&#xD;
      recommended for hepatectomy and can benefit from the surgery,and because of the unsatisfied&#xD;
      outcome,patients with a NDR score more than 2 are not recommended for hepatectomy.The&#xD;
      stringent selection criteria should be expanded so that more patients can benefit from&#xD;
      hepatectomy,and the less stringent criteria should be limited to ensure curative&#xD;
      effect.So,the investigators' NDR scoring system was more accurate in selecting patients with&#xD;
      multiple HCCs for hepatectomy and this article was published on Ann Surg&#xD;
      Oncol（2015，22:826）.In order to further confirm the rationality of this selection criteria,the&#xD;
      investigators would like to propose a prospective randomized controlled study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Hepatectomy with NDR 0-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE with NDR 0-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatectomy with NDR &gt;2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE with NDR &gt;2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatectomy</intervention_name>
    <description>Surgical removal of all lesions</description>
    <arm_group_label>Hepatectomy with NDR 0-2</arm_group_label>
    <arm_group_label>Hepatectomy with NDR &gt;2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Transarterial chemoembolization with lipiodol and pirarubicin</description>
    <arm_group_label>TACE with NDR 0-2</arm_group_label>
    <arm_group_label>TACE with NDR &gt;2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients &gt; 18 years and &lt;=70 years of age&#xD;
&#xD;
          2. Patients preoperatively diagnosed of hepatocellular carcinoma according to the&#xD;
             criteria of American Association for the Study of Liver Diseases(AASLD).&#xD;
&#xD;
          3. Preoperative ECOG criteria score of 0-1&#xD;
&#xD;
          4. Child-Pugh class A liver function&#xD;
&#xD;
          5. Multiple hepatocellular carcinomas with tumor number &lt;=5 and total tumor diameter &lt;=15&#xD;
             cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major portal/hepatic vein invasion&#xD;
&#xD;
          2. Extrahepatic metastasis&#xD;
&#xD;
          3. Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may&#xD;
             affect the treatment of liver cancer&#xD;
&#xD;
          4. Anticancer treatment before surgery&#xD;
&#xD;
          5. Lost to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Feng, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shen Feng, MD</last_name>
    <phone>0086-021-25070805</phone>
    <email>shenfengdfgd@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eastern hepatobilliary surgery hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Xia, Doctor</last_name>
      <phone>86-021-81875495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern hepatobilliary surgery hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Feng, MD</last_name>
      <phone>0086-021-25070805</phone>
      <email>shenfengdfgd@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wu Dong, MD</last_name>
      <phone>0086-021-25070765</phone>
      <email>wuyuz@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Shen Feng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>ShenFeng</investigator_full_name>
    <investigator_title>vice president of the Eastern Hepatobiliary Surgery Hospital</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Hepatectomy</keyword>
  <keyword>Transarterial Chemoembolization</keyword>
  <keyword>Scoring System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

